ArticleJournal of orthopaedic surgery and research2026
Parameter-screened LED therapy targets STAT3/IL-6 axis to attenuate tendinopathy via dual modulation of inflammation and ECM remodeling.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundLight-emitting diode (LED) therapy is a promising non-invasive approach for tendinopathy, yet clinical adoption is hindered by heterogeneous treatment parameters and undefined molecular mechanisms. The role of the Interleukin (IL)-6/signal transducer and activator of transcription 3(STAT3) signaling axis in LED-mediated tendon repair remains unexplored.
objectiveThis study aimed to screen effective LED parameters for mitigating tendinopathy by evaluating their effects on inflammation and extracellular matrix (ECM) synthesis in tenocytes, to preliminarily explore the role of the IL-6/STAT3 axis, and to validate the anti-inflammatory and pro-repair effects of selected parameters in a rodent model.
methodsTenocytes from 8 week-old male Sprague-Dawley rat's Achilles's tendon were cultured and stimulated with IL-1β to model inflammatory tendinopathy. Cells underwent LED irradiation at varying wavelengths (625 nm, 810 nm, 940 nm) and energy densities. Cell viability was assessed via CCK-8 assay; expression of inflammatory markers (IL-6, Substance P (SP)), ECM components (type I collagen (COL1), type III collagen (COL3), and lubricin (PRG4) was quantified using qPCR, Western blot, and immunofluorescence to determine optimal LED parameters. STAT3 inhibition was applied to IL-1β-stimulated cells before LED treatment to probe STAT3's role. In vivo, collagenase-I was injected into rat Achilles tendons to induce tendinopathy, followed by LED therapy. Pain thresholds were measured using von Frey filaments, tendon histopathology was evaluated via Hematoxylin and Eosin (H&E) staining and modified Bonar scoring, and expression of COL1, COL3, IL-6, SP, and PRG4 was assessed by immunofluorescence and immunohistochemistry.
resultsLED irradiation at 625 nm/52.8 J/cm
conclusionsIL-1β disrupts tendon homeostasis by driving inflammation and ECM degradation. LED therapy at 625 nm/52.8 J/cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.